Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91

Amphastar Pharmaceuticals, Inc.

Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.
GAAP net income $30.3M ($0.67 diluted EPS) vs $31.0M ($0.64) year ago.
Adjusted non-GAAP net income $40.8M ($0.91 diluted EPS) vs $40.9M ($0.85).
CEO cites revenue growth, gross margin expansion, new product launches, and pipeline progress.
Six-month 2026 GAAP net income $36.8M ($0.81) vs $56.3M ($1.15) in prior year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.